TY - JOUR
T1 - Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
AU - Kowdley, Kris V.
AU - Bowlus, Christopher L.
AU - Levy, Cynthia
AU - Mayo, Marlyn J.
AU - Pratt, Daniel S.
AU - Vuppalanchi, Raj
AU - Younossi, Zobair M.
N1 - Publisher Copyright:
© 2023 Wolters Kluwer Health. All rights reserved.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease and its complications. A previous expert review panel collaborated on a consensus document for gastroenterologists and other healthcare professionals regarding the care of patients with PBC. Subsequently, there have been several recent important developments in the diagnosis, treatment, and monitoring of patients with PBC. These include updates to prognostic models on risk stratification, new noninvasive tools for staging of disease, updates to the appropriate use of and long-term treatment results with obeticholic acid as a second-line treatment, the emerging therapeutic role of fibrates, and the advancement of investigational agents for managing PBC. In this updated expert consensus document, we provide updates on staging, the use of noninvasive prognostic tools, and a treatment algorithm to provide evidence-based and practical tools for clinicians who manage PBC, with the ultimate goal to improve the long-term outcomes for patients with this chronic liver disease.
AB - Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease and its complications. A previous expert review panel collaborated on a consensus document for gastroenterologists and other healthcare professionals regarding the care of patients with PBC. Subsequently, there have been several recent important developments in the diagnosis, treatment, and monitoring of patients with PBC. These include updates to prognostic models on risk stratification, new noninvasive tools for staging of disease, updates to the appropriate use of and long-term treatment results with obeticholic acid as a second-line treatment, the emerging therapeutic role of fibrates, and the advancement of investigational agents for managing PBC. In this updated expert consensus document, we provide updates on staging, the use of noninvasive prognostic tools, and a treatment algorithm to provide evidence-based and practical tools for clinicians who manage PBC, with the ultimate goal to improve the long-term outcomes for patients with this chronic liver disease.
UR - http://www.scopus.com/inward/record.url?scp=85147457974&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000002070
DO - 10.14309/ajg.0000000000002070
M3 - Review article
C2 - 36729104
AN - SCOPUS:85147457974
SN - 0002-9270
VL - 118
SP - 232
EP - 242
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 2
ER -